TBB (CAS 17374-26-4)

TBB (4,5,6,7-Tetrabromobenzotriazole) is an organic compound widely employed in diverse scientific research. TBBT possesses a benzotriazole core with four bromine atoms attached to it, rendering it an aromatic compound. Its stability against light and heat degradation makes it an optimal choice for various research endeavors. This crystalline, white solid is a cell-permeable benzotriazolo compound renowned for its capacity to selectively inhibit protein kinases by competitively binding to ATP/GTP-binding sites. Specifically, it demonstrates potent inhibition against casein kinase IIα (CK2α) and dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (Dyrk1A). The strong binding ability of TBB is attributed to both hydrophobic and van der Waals interactions. While it exhibits a lesser extent of inhibition towards kinases such as glycogen synthase kinase (GSK), cyclin-dependent kinase 2 (CDK2), and phosphorylase kinase, it has shown inhibition against NS3-associated viral helicase activities in hepatitis C virus and West Nile virus. Moreover, TBB has been employed as an apoptotic inducer in Jurkat cells. Moreover, it is postulated that TBB acts as an inhibitor of cyclooxygenase (COX) enzymes. COX enzymes participate in the synthesis of prostaglandins, which play roles in processes like inflammation, pain modulation, and other physiological responses. By hindering COX activity, TBB can effectively decrease prostaglandin production, potentially providing therapeutic benefits for specific conditions. Thus, TBB has found utility in numerous in vitro studies investigating its impact on cell growth, differentiation, and immune system function. Its effects on the central nervous system and its potential applications in cancer therapy have also been explored extensively.